USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CENTROSE, LLC
Address:
918 Deming Way, STE 100
MADISON, WI 53717-1945
Phone:
N/A
URL:
N/A
EIN:
120580744
DUNS:
787342471
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,457,226.00 7
STTR Phase I $75,000.00 1

Award List:

novel macrolides as anti-infective drugs

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$244,089.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Although it has long been known that macrolide glycosylation is absolutely essential for antibacterial activity, the megalomicins (which differ from erythromycins solely via an additional sugar attached at C6 of the mac rolide) were the first macrolides to… More

cardiac neoglycosides as cancer drugs

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$163,192.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Epidemiological evidence points to the value of cardiac glycosides like digoxin and digitoxin for treatment of breast cancer and recent reports suggest they may be especially useful to treat non-small cell lung cancer. These and other findings underlie our… More

STTR Phase I: Development of Bacterial Glycorandomization Hosts

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$75,000.00
Agency:
NSF
Principal Investigator:
Research Institution:
University of Wisconsin- Madison
RI Contact:
Jon S. Thorson
Abstract:
This Small Business Technology Transfer Research Phase I project develops methodology needed for the production of sugar enhanced (glycosidic) compound libraries and final therapeutic leads. Sugar attachments have been identified as a powerful way to make therapeutically relevant small molecules.… More

Automation of Neoglycoside Synthesis

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$198,836.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The process of small molecule and natural product glycorandomization developed by Thorson and coworkers has been validated as one of the first simple, efficient and general glycosylation strategies for small molecule an d macromolecular therapeutics. Given its… More

Amphotericin B Analogs

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$277,253.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Current antifungal therapy is limited by the types of drugs available to treat systemic infections due to emerging and comparatively rare fungi different from the common strains of pathogenic Candida, Aspergillus, Crypt ococcus and the Zygomycoses. Neutropenic… More

SBIR Phase I: Development of a High Throughput Glycosyl-Scanning Platform

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$150,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research Phase I project highlights a strategy for the development of the first integrated high throughput pipeline to synthesize and evaluate novel sugar-drug conjugates. The core innovation of this proposed phase I study is an enzyme catalyzed one-step glycosylation… More

A new paradigm for antibody-directed conjugates

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$199,122.00
Agency:
HHS
Principal Investigator:
James R. Prudent – 608-836-0207
Abstract:
DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is among the most common and lethal cancers yet, the current standard of care for advanced stage NSCLC provides only modest improvements in overall survival or quality of life. Thus,there exists a significant unmet need for new… More

A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$224,734.00
Agency:
HHS
Principal Investigator:
James R. Prudent – 608-836-0207
Abstract:
Project Summary The incidence of renal cell cancer has been rising steadily and for those that have tumor recurrence after surgery, the prognosis is generally poor. In 2013 an estimated 65,150 new cases and 13,680 deaths will be attributed to renal cancerin the United States. Renal cancer is the… More